JP2004506722A - ペルオキシソーム増殖因子活性化受容体の調節方法 - Google Patents

ペルオキシソーム増殖因子活性化受容体の調節方法 Download PDF

Info

Publication number
JP2004506722A
JP2004506722A JP2002521433A JP2002521433A JP2004506722A JP 2004506722 A JP2004506722 A JP 2004506722A JP 2002521433 A JP2002521433 A JP 2002521433A JP 2002521433 A JP2002521433 A JP 2002521433A JP 2004506722 A JP2004506722 A JP 2004506722A
Authority
JP
Japan
Prior art keywords
methyl
phenyl
oxazol
ethoxy
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2002521433A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004506722A5 (OSRAM
Inventor
ロバート・ジェイ・アーデッキー
ドーン・アリサ・ブルックス
アレキサンダー・グレン・ゴッドフリー
サラ・ベス・ジョーンズ
ネーサン・ブライアン・マントロ
ジェイムズ・レイ・マッカーシー
ピエール−イヴ・ミシェリー
クリストファー・ジョン・リト
ジョン・エス・タイホナス
レナード・ラリー・ウィネロスキー
シュ・ヤンピン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of JP2004506722A publication Critical patent/JP2004506722A/ja
Publication of JP2004506722A5 publication Critical patent/JP2004506722A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2002521433A 2000-08-23 2001-08-23 ペルオキシソーム増殖因子活性化受容体の調節方法 Withdrawn JP2004506722A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22745600P 2000-08-23 2000-08-23
PCT/US2001/022617 WO2002016332A1 (en) 2000-08-23 2001-08-23 Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists

Publications (2)

Publication Number Publication Date
JP2004506722A true JP2004506722A (ja) 2004-03-04
JP2004506722A5 JP2004506722A5 (OSRAM) 2008-10-09

Family

ID=22853183

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002521433A Withdrawn JP2004506722A (ja) 2000-08-23 2001-08-23 ペルオキシソーム増殖因子活性化受容体の調節方法

Country Status (10)

Country Link
US (1) US7176224B2 (OSRAM)
EP (1) EP1313717B1 (OSRAM)
JP (1) JP2004506722A (OSRAM)
AT (1) ATE375985T1 (OSRAM)
AU (1) AU2001284660A1 (OSRAM)
CA (1) CA2418134A1 (OSRAM)
DE (1) DE60131001T2 (OSRAM)
ES (1) ES2295200T3 (OSRAM)
MX (1) MXPA03001610A (OSRAM)
WO (1) WO2002016332A1 (OSRAM)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005502600A (ja) * 2001-06-07 2005-01-27 イーライ・リリー・アンド・カンパニー ペルオキシソーム増殖因子活性化受容体（ｐｐａｒ）のモジュレーター
WO2007013694A1 (ja) * 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited フェノキシアルカン酸化合物

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002018355A1 (en) 2000-08-23 2002-03-07 Eli Lilly And Company Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
HUP0300857A3 (en) 2000-08-23 2007-03-28 Lilly Co Eli Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
US7192982B2 (en) * 2001-06-07 2007-03-20 Ligand Pharmaceuticals, Inc. Modulators of peroxisome proliferator activated receptors
CN1293076C (zh) * 2001-10-12 2007-01-03 日本化学医药株式会社 过氧化物酶体增殖剂应答性受体δ的活化剂
US20050080115A1 (en) * 2002-10-28 2005-04-14 Lone Jeppesen Novel compounds, their preparation and use
KR100699614B1 (ko) * 2002-11-08 2007-03-23 에프. 호프만-라 로슈 아게 퍼옥시좀 증식자 활성화된 수용체 작용제로서의 치환된4-알콕시옥사졸 유도체
US7192970B2 (en) * 2002-11-26 2007-03-20 Chipscreen Biosciences, Ltd. Noncyclic 1,3-dicarbonyl compounds as dual PPAR agonists with potent antihyperglycemic and antihyperlipidemic activity
CA2512883A1 (en) 2003-02-14 2004-09-02 Eli Lilly And Company Sulfonamide derivatives as ppar modulators
DE102004060227B3 (de) 2004-12-15 2006-07-20 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Oxazolen durch Kondensation von aromatischen Aldehyden mit α-Ketoximen zu N-Oxiden und nachfolgende Reaktion mit aktivierten Säurederivaten
KR20120051670A (ko) 2009-08-05 2012-05-22 다이이찌 산쿄 가부시키가이샤 아미드 유도체
HRP20150225T1 (hr) * 2010-10-14 2015-06-19 Daiichi Sankyo Company, Limited Derivati acilbenzena

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089514A (en) * 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
US5232945A (en) * 1992-07-20 1993-08-03 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
US5902726A (en) * 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
CA2245529A1 (en) 1996-02-02 1997-08-07 Soumya P. Sahoo Antidiabetic agents
GB9604242D0 (en) 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
KR20000068151A (ko) * 1996-08-19 2000-11-25 미즈노 마사루 프로피온산 유도체 및 그의 용도
AU3275999A (en) * 1998-03-10 1999-09-27 Ono Pharmaceutical Co. Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
US6417212B1 (en) * 1999-08-27 2002-07-09 Eli Lilly & Company Modulators of peroxisome proliferator activated receptors
JP4316787B2 (ja) 2000-01-11 2009-08-19 壽製薬株式会社 エーテル又はアミド誘導体、その製法並びにそれを含有する糖尿病治療剤、
HUP0300857A3 (en) 2000-08-23 2007-03-28 Lilly Co Eli Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
WO2002018355A1 (en) 2000-08-23 2002-03-07 Eli Lilly And Company Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005502600A (ja) * 2001-06-07 2005-01-27 イーライ・リリー・アンド・カンパニー ペルオキシソーム増殖因子活性化受容体（ｐｐａｒ）のモジュレーター
WO2007013694A1 (ja) * 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited フェノキシアルカン酸化合物

Also Published As

Publication number Publication date
US7176224B2 (en) 2007-02-13
WO2002016332A1 (en) 2002-02-28
EP1313717B1 (en) 2007-10-17
ES2295200T3 (es) 2008-04-16
DE60131001T2 (de) 2008-07-17
AU2001284660A1 (en) 2002-03-04
US20040138277A1 (en) 2004-07-15
CA2418134A1 (en) 2002-02-28
DE60131001D1 (de) 2007-11-29
ATE375985T1 (de) 2007-11-15
MXPA03001610A (es) 2003-09-10
EP1313717A1 (en) 2003-05-28

Similar Documents

Publication Publication Date Title
US6825222B2 (en) Modulators of peroxisome proliferator activated receptors
US6982278B2 (en) Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
US7153878B2 (en) Peroxisome proliferator activated receptor modulators
EP1480642A1 (en) Peroxisome proliferator activated receptor modulators
EP1313716B1 (en) Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
JP2004506722A (ja) ペルオキシソーム増殖因子活性化受容体の調節方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080820

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080820

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20080911

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20081027